Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Using AUA Guidelines
This AUA guideline is provided free of charge to the general public for clinical, academic, research and educational use purposes only. Any person or company accessing or using AUA guidelines for promotional or commercial purposes must request a license for use. To request a license for this guideline, please contact Keith Price at kprice@AUAnet.org.
(Published 2016; Amended 2020, 2024)
To cite this guideline:
Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. https://www.auajournals.org/doi/10.1097/JU.0000000000003846
Unabridged version of this Guideline [pdf]
Guideline Amendment Summary [pdf]
Algorithm associated with this Guideline [pdf]
AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer
Español translated guideline courtesy of Confederación Americana de Urologia (CAU) [pdf]
Panel Members
Sam S. Chang, MD, MBA; Stephen A. Boorjian, MD; Roger Chou, MD; Peter E. Clark, MD; Siamak Daneshmand, MD; Badrinath R. Konety, MD, FACS, MBA; Raj Pruthi, MD, FACS; Diane Z. Quale; Chad R. Ritch, MD, MBA; John D. Seigne, MD; Eila Curlee Skinner, MD; Norm D. Smith, MD; James M. McKiernan, MD